SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Stemline Therapeutics, Inc.
Sponsor:
Collaborator:
The Leukemia and Lymphoma Society
Information provided by (Responsible Party):
Stemline Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT02113982
First received: March 13, 2014
Last updated: July 1, 2016
Last verified: July 2016
  Purpose
This is a non-randomized, open-label, multi center study. A cycle of therapy is 5 consecutive days every 21 days for 6 or more cycles. Stage I will consist of a brief run-in period in which patients with BPDCN (previously untreated and previously treated) and AML (persistent/recurrent and previously untreated) will be treated with SL-401 at 3 dose levels. During Stage 2, two cohorts of BPDCN and AML patients will be treated at the maximum tolerated dose or maximum tested dose in which multiple dose-limiting toxicities are not observed (identified in Stage 1).

Condition Intervention Phase
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Acute Myeloid Leukemia
Drug: SL-401
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Resource links provided by NLM:


Further study details as provided by Stemline Therapeutics, Inc.:

Primary Outcome Measures:
  • Primary Outcome Measures include Efficacy and Safety [ Time Frame: Please refer to the Study Completion date ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: September 2014
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: September 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SL-401 Drug: SL-401

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Stage 1

Inclusion Criteria:

  1. The patient has a diagnosis of AML or BPDCN according to WHO classification (AML; excluding acute promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN)
  2. The patient must meet one of the following (a) or (b) or (c):

    1. Has evidence of persistent or recurrent AML in the peripheral blood and/or bone marrow that is refractory to, or has relapsed from, their most recent prior line of treatment.

      • A prior line of treatment is considered an induction regimen if it involves an approved or investigational cytotoxic chemotherapy agent, biological agent, and/or hypomethylating agent administered alone or in a combination regimen, with the intent to induce robust cytoreduction (i.e., CR).
      • The previous induction regimen may have been a SCT with intent to induce a CR.
      • Consolidation and/or maintenance (including SCT) may have been given in CR/CRi, but are not counted as a line of treatment.
      • Hydroxyurea will not be considered a prior line of treatment.
    2. Has previously untreated AML and is considered to be at high risk for disease progression and/or is unlikely to derive more than transient benefit from standard therapy by having at least one of the following:

      • Treatment-related AML, except if it is associated with favorable cytogenetics (e.g., inversion 16, t(16;16), t(8;21), t(15;17)).
      • AML with antecedent hematological disease (e.g., myelodysplastic syndrome (MDS), myelofibrosis, polycythemia vera, etc.) and not a candidate for stem cell transplantation (SCT) in their current disease state.
    3. Has histological and/or cytological evidence of BPDCN in the peripheral blood, bone marrow, spleen, lymph nodes, skin, and/or other sites that is either previously untreated or is persistent/recurrent following prior treatment for BPDCN.
  3. The patient is ≥ 18 years old.
  4. The patient has an ECOG performance score (PS) of 0-2.
  5. The patient has adequate baseline organ function, including cardiac, renal, and hepatic function:

    • Left ventricular ejection fraction (LVEF) ≥ 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG
    • Serum creatinine ≤ 1.5 mg/dl
    • Serum albumin ≥ 3.0 g/dl
    • Bilirubin ≤ 1.5 mg/dl
    • AST and ALT ≤ 2.5 times the upper limit of normal (ULN)
  6. If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 1 week prior to treatment.
  7. The patient has signed informed consent prior to initiation of any study-specific procedures or treatment.
  8. The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.

Inclusion Criteria:

  1. The patient has a diagnosis of AML or BPDCN according to WHO classification (AML; excluding acute promyelocytic leukemia [APL, FAB M3]) or confirmed by hematopathology (BPDCN)
  2. The patient must meet one of the following (a) or (b) or (c):

    1. Has evidence of persistent or recurrent AML in the peripheral blood and/or bone marrow that is refractory to, or has relapsed from, their most recent prior line of treatment.

      • A prior line of treatment is considered an induction regimen if it involves an approved or investigational cytotoxic chemotherapy agent, biological agent, and/or hypomethylating agent administered alone or in a combination regimen, with the intent to induce robust cytoreduction (i.e., CR).
      • The previous induction regimen may have been a SCT with intent to induce a CR.
      • Consolidation and/or maintenance (including SCT) may have been given in CR/CRi, but are not counted as a line of treatment.
      • Hydroxyurea will not be considered a prior line of treatment.
    2. Has previously untreated AML and is considered to be at high risk for disease progression and/or is unlikely to derive more than transient benefit from standard therapy by having at least one of the following:

      • Treatment-related AML, except if it is associated with favorable cytogenetics (e.g., inversion 16, t(16;16), t(8;21), t(15;17)).
      • AML with antecedent hematological disease (e.g., myelodysplastic syndrome (MDS), myelofibrosis, polycythemia vera, etc.) and not a candidate for SCT in their current disease state.
    3. Has histological and/or cytological evidence of BPDCN in the peripheral blood, bone marrow, spleen, lymph nodes, skin, and/or other sites that is either previously untreated or is persistent/recurrent following prior treatment for BPDCN.
  3. The patient is ≥ 18 years old.
  4. The patient has an ECOG performance score (PS) of 0-2.
  5. The patient has adequate baseline organ function, including cardiac, renal, and hepatic function:

    • Left ventricular ejection fraction (LVEF) ≥ 40% as measured by MUGA scan or 2-D ECHO within 28 days prior to start of therapy and no clinically significant abnormalities on a 12-lead ECG
    • Serum creatinine ≤ 1.5 mg/dl
    • Serum albumin ≥ 3.0 g/dl
    • Bilirubin ≤ 1.5 mg/dl
    • AST and ALT ≤ 2.5 times the upper limit of normal (ULN)
  6. If the patient is a woman of child bearing potential (WOCBP), she has had a negative serum or urine pregnancy test within 1 week prior to treatment.
  7. The patient has signed informed consent prior to initiation of any study-specific procedures or treatment.
  8. The patient is able to adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment.
  9. The patient (male and female) agrees to use acceptable contraceptive methods for the duration of time on the study, and continue to use acceptable contraceptive methods for 2 months after the last infusion of SL-401.

Exclusion Criteria:

  1. The patient has a diagnosis of acute promyelocytic leukemia (APL; FAB M3).
  2. The patient has persistent clinically significant toxicities Grade ≥ 2 from previous chemotherapy (excluding alopecia, nausea, fatigue, and liver function tests (as mandated in the inclusion criteria)).
  3. The patient has received treatment with chemotherapy, wide-field radiation, or biologic therapy within 14 days of study entry.
  4. The patient has received treatment with another investigational agent within 14 days of study entry.
  5. The patient has previously received treatment with SL-401.
  6. The patient has an active malignancy and/or cancer history (excluding AML, BPDCN, or antecedent MDS) that may confound the assessment of the study endpoints. Patients with a past cancer history (within 2 years of entry) with substantial potential for recurrence and/or ongoing active malignancy must be discussed with the Sponsor before study entry. Patients with the following neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, cervical intraepithelial neoplasia, organ-confined prostate cancer with no evidence of progressive disease.
  7. The patient has clinically significant cardiovascular disease (e.g., uncontrolled or any NYHA Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction or stroke within 6 months of study entry, uncontrolled hypertension or clinically significant arrhythmias not controlled by medication).
  8. The patient has uncontrolled, clinically significant pulmonary disease (e.g., COPD, pulmonary hypertension) that in the opinion of the investigator would put the patient at significant risk for pulmonary complications during the study.
  9. The patient has known active or suspected CNS leukemia. If suspected, CNS leukemia should be ruled out with relevant imaging and/or examination of cerebrospinal fluid.
  10. The patient is receiving immunosuppressive therapy - with the exception of low-dose prednisone (≤ 10 mg/day) - for treatment or prophylaxis of graft-versus-host disease (GVHD). If the patient has been on immunosuppressive treatment or prophylaxis for GVHD, the treatment(s) must have been discontinued at least 14 days prior to study treatment and there must be no evidence of Grade ≥ 2 GVHD.
  11. The patient has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, DIC, or psychiatric illness/social situations that would limit compliance with study requirements.
  12. The patient is pregnant or breast feeding.
  13. The patient has known positive status for human immunodeficiency virus (HIV) active or chronic Hepatitis B or Hepatitis C.
  14. The patient is oxygen-dependent.
  15. The patient has any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities.

Stage 2

BPDCN and AML patients will be grouped separately.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02113982

Contacts
Contact: Shay Shemesh, MS 646-502-2310 Trials@stemline.com

Locations
United States, California
City of Hope National Medical Center Recruiting
Duarte, California, United States, 91010
Contact    626-256-4673      
Principal Investigator: Anthony Stein, MD         
United States, Florida
H. Lee Moffiitt Cancer Center & Research Institute Recruiting
Tampa, Florida, United States, 12902
Contact    888-663-3488      
Principal Investigator: Kendra Sweet, MD         
United States, Massachusetts
Dana Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact    617-632-3000      
Principal Investigator: Andrew Lane, MD         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact    716-845-2300      
Principal Investigator: Eunice S Wang, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27705
Contact    919-668-1027      
Principal Investigator: David Rizzieri, MD         
United States, Ohio
Ohio State University Recruiting
Columbus, Ohio, United States, 43210
Contact    614-293-8652      
Principal Investigator: Sumithira Vasu, MD         
United States, Pennsylvania
University of Pittsburgh Medical Center Presbyterian Shady Side Recruiting
Pittsbirgh, Pennsylvania, United States, 15213
Contact: Oleg Akilov, MD    412-647-4200    akilovoe@upmc.edu   
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact    713-792-2121      
Principal Investigator: Marina Konopleva, MD         
Sponsors and Collaborators
Stemline Therapeutics, Inc.
The Leukemia and Lymphoma Society
  More Information

Responsible Party: Stemline Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02113982     History of Changes
Other Study ID Numbers: STML-401-0114 
Study First Received: March 13, 2014
Last Updated: July 1, 2016
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leukemia
Neoplasms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type

ClinicalTrials.gov processed this record on July 25, 2016